Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10837003
APP PUB NO 20180010099A1
SERIAL NO

15710672

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blaney, Joseph Gettysburg, US 5 73
Falgout, Barry Rockville, US 7 84
Hanley, Kathryn Las Cruces, US 5 73
Lai, Ching-Juh Bethesda, US 31 232
Markoff, Lewis Bethesda, US 9 105
Murphy, Brian R Bethesda, US 96 972
Whitehead, Stephen S Montgomery Village, US 52 355

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 17, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 17, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00